News Headlines Article

Alzheimer drug shows some promise in mild disease
San Francisco Chronicle

Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies on the drug — Eli Lilly & Co.’s solanezumab — missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled results found 34 percent less mental decline in mild Alzheimer’s patients compared to those on a fake treatment for 18 months.

Commands